Important unknowns about Novartis's potential paradigm shifter LCZ696
This article was originally published in Scrip
Executive Summary
Despite the $8.3bn boost to Novartis's stock market capitalization yesterday on the positive trial news for the novel drug LCZ696 in chronic heart failure, consequential details remain unknown.